Cargando…

Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer

OBJECTIVES: Various genomic alterations and genomic signatures, including ERBB2 amplification, mutations in PIK3CA, AKT1, and ESR1, and tumor mutational burden (TMB), have become important biomarkers for treatment selection in breast cancer (BC). This study aimed to investigate the mutational featur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Weikai, Zhang, Guochun, Chen, Bo, Chen, Xiaoqing, Wen, Lingzhu, Lai, Jianguo, Li, Xuerui, Li, Min, Liu, Hao, Liu, Jing, Han-Zhang, Han, Lizaso, Analyn, Liao, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096980/ https://www.ncbi.nlm.nih.gov/pubmed/33968723 http://dx.doi.org/10.3389/fonc.2021.618767

Ejemplares similares

Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics
por: Xiao, Weikai, et al.
Publicado: (2021)

Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer
por: Chen, Bo, et al.
Publicado: (2020)

Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients
por: Wen, Lingzhu, et al.
Publicado: (2021)

Spectrum of MAP3K1 mutations in breast cancer is luminal subtype-predominant and related to prognosis
por: Li, Cheukfai, et al.
Publicado: (2022)

Association of Body Mass Index With Somatic Mutations in Breast Cancer
por: Chen, Bo, et al.
Publicado: (2021)

Analysis of Prognostic Factors Affecting the Brain Metastases Free Survival and Survival After Brain Metastases in Breast Cancer
por: Xiao, Weikai, et al.
Publicado: (2020)

Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients
por: Tao, Zhonghua, et al.
Publicado: (2020)

Heterogenous and Low Expression of HER2 in Breast Cancer Overcome by DS-8201a in a Heavily Treated Patient: Case Report and Review of the Literature
por: Li, Cheukfai, et al.
Publicado: (2022)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Prevalence of ESR1 Mutation in Chinese ER-Positive Breast Cancer
por: Zhu, Wenzhen, et al.
Publicado: (2020)

Molecular characterization of breast cancer: a potential novel immune-related lncRNAs signature
por: Lai, Jianguo, et al.
Publicado: (2020)

Characteristics of Pan-Cancer Patients With Ultrahigh Tumor Mutation Burden
por: Yuan, Hong, et al.
Publicado: (2021)

High tumor mutation burden indicates better prognosis in colorectal cancer patients with KRAS mutations
por: Wang, Jianlei, et al.
Publicado: (2022)

FAT3 Mutation Is Associated With Tumor Mutation Burden and Poor Prognosis in Esophageal Cancer
por: Guo, Zixin, et al.
Publicado: (2021)

Tumor mutation burden derived from small next generation sequencing targeted gene panel as an initial screening method
por: Tang, Yuan, et al.
Publicado: (2020)

The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients
por: Lin, Quan, et al.
Publicado: (2019)

Next-Generation Sequencing Reveals High Uncommon EGFR Mutations and Tumour Mutation Burden in a Subgroup of Lung Cancer Patients
por: Guo, Gang, et al.
Publicado: (2021)

MicroRNAs Expression Patterns Predict Tumor Mutational Burden in Colorectal Cancer
por: Huang, Jiahao, et al.
Publicado: (2021)

PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations
por: Ma, Tiantian, et al.
Publicado: (2022)

Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
por: Li, Kai, et al.
Publicado: (2020)

Tumor Mutational Burden Associated With Response to Hyperthermic Intraperitoneal Chemotherapy
por: Zeng, Lisi, et al.
Publicado: (2022)

APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer
por: Natesan, Divya, et al.
Publicado: (2022)

Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy
por: Duan, Xiao-Peng, et al.
Publicado: (2023)

Identification of a novel microRNA recurrence-related signature and risk stratification system in breast cancer
por: Lai, Jianguo, et al.
Publicado: (2019)

Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours
por: Chen, Bo, et al.
Publicado: (2021)

Targeted sequencing identifies the mutational signature of double primary and metastatic malignancies: a case report
por: Rao, Chuangzhou, et al.
Publicado: (2019)

Blood Tumor Mutational Burden as a Predictive Biomarker in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
por: Ma, Yuhui, et al.
Publicado: (2021)

The Clinical Implications of Tumor Mutational Burden in Osteosarcoma
por: Xie, Lu, et al.
Publicado: (2021)

Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Huang, Taobi, et al.
Publicado: (2021)

Integrating Histologic and Genomic Characteristics to Predict Tumor Mutation Burden of Early-Stage Non-Small-Cell Lung Cancer
por: Qiu, Yuan, et al.
Publicado: (2021)

DNA methylation-based patterns for early diagnostic prediction and prognostic evaluation in colorectal cancer patients with high tumor mutation burden
por: Huang, Hao, et al.
Publicado: (2023)

Precise Identification of Recurrent Somatic Mutations in Oral Cancer Through Whole-Exome Sequencing Using Multiple Mutation Calling Pipelines
por: Lin, Li-Han, et al.
Publicado: (2021)

Gene Mutations Associated With Clinical Characteristics in the Tumors of Patients With Breast Cancer
por: Hao, Chunfang, et al.
Publicado: (2022)

TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy
por: Liu, Surui, et al.
Publicado: (2022)

Prognostic analysis of patients with breast cancer based on tumor mutational burden and DNA damage repair genes
por: Teng, Xu, et al.
Publicado: (2023)

Immunotherapy and tumor mutational burden in cancer patients with liver metastases: A meta and real word cohort analysis
por: Wu, Rui-Yan, et al.
Publicado: (2023)

Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy
por: Wang, Peipei, et al.
Publicado: (2021)

Analysis of BRCA Germline Mutations in Chinese Prostate Cancer Patients
por: Chen, Wei, et al.
Publicado: (2022)

Correlation of tumor mutational burden with prognosis and immune infiltration in lung adenocarcinoma
por: Li, Lin, et al.
Publicado: (2023)

Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer
por: Lin, Chen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_795dqmuje62bah85379le15jjm